Welcome Back
Join CoinTime
Sign in with email
Sign up with email
Check your inbox
Prothena
About
Prothena is a clinical-stage neuroscience company focused on the discovery and development of novel therapies.
- South San Francisco,California,United States
- 51 - 100
- http://prothena.com
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $172.40M
- Industries
- Biotechnology,Health Care,Health Diagnostics
- Founded date
- Jan 1, 2012
- Number Of Employee
- 51 - 100
- Operating Status
- Active
- Stock Symbol
- nasdaq:PRTA
- Legal Name
- Prothena Corporation plc
Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a pipeline of novel investigational therapeutics with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 14, 2022 | Post-IPO Equity | $172.40M | — | — | — | Detail |
| May 10, 2021 | Post-IPO Equity | $60M | — | — | — | Detail |
| Mar 24, 2021 | Post-IPO Equity | $67.80M | — | — | — | Detail |
| Mar 29, 2018 | Post-IPO Equity | $49.99M | — | — | — | Detail |
| Mar 3, 2017 | Post-IPO Equity | $155.30M | — | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Sofinnova Investments
|
— | Post-IPO Equity |
Employee Profiles
